General
Preferred name
CLOFIBRATE
Synonyms
Ethyl clofibrate ()
Clofibratum ()
Clofibrato ()
Clofibrate ()
NSC-79389 ()
ICI 28257 ()
ICI-28257 ()
AY-61123 ()
Chlorfenisate ()
Atromid ()
Ethyl p-chlorophenoxyisobutyrate ()
Atromid-S ()
P&D ID
PD001476
CAS
637-07-0
882-09-7
Tags
available
prodrug
drug
Approved by
FDA
First approval
1967
Drug indication
Cardiovascular disease
Dysbetalipoproteinemia
Drug Status
approved
withdrawn
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
The marketing of many formulations of clifobrate has been discontinued
(GtoPdb)
DESCRIPTION
Clofibrate is an agonist of PPAR, with EC50s of 50 ¦ÌM, ¡«500 ¦ÌM for murine PPAR¦Á and PPAR¦Ã, and 55 ¦ÌM, ¡«500 ¦ÌM for human PPAR¦Á and PPAR¦Ã, respectively.
PRICE
29
DESCRIPTION
Clofibrate is a fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Antihyperlipoproteinemic; increases lipoprotein lipase activity, thus enhancing the rate of intravascular catabolism of ULDL to IDL and LDL
(LOPAC library)
DESCRIPTION
Clofibrate is a fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia.
(Enamine Bioactive Compounds)
DESCRIPTION
Clofibrate (Clofibrato) is an aryloxyisobutyric acid derivate with antihyperlipidemic activity.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
28
AdooQ Bioactive Compound Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
LOPAC library
MedChem Express Bioactive Compound Library
NPC Screening Collection
NURSA ligand set
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
41
Molecular Weight
242.07
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
0
Rotatable Bonds
4
Ring Count
1
Aromatic Ring Count
1
cLogP
3.06
TPSA
35.53
Fraction CSP3
0.42
Chiral centers
0.0
Largest ring
6.0
QED
0.76
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
Lipoprotein lipase
MOA
peroxisome proliferator-activated receptor agonist
PPAR receptor agonist
Target
Peroxisome proliferator-activated receptor alpha
PPAR
PPARα
LPL, PPARA
Indication
hyperlipidemia, cholesterol
Disease Area
endocrinology, cardiology
ATC
C10AB01
Pathway
DNA Damage/DNA Repair
Metabolism
Cell Cycle/DNA Damage
Metabolic Enzyme/Protease
Vitamin D Related/Nuclear Receptor
Therapeutic Class
Antilipemic Agents
Source data
